Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 18 of 46

Controlled Studies in This CER: Adding Nonbiologic DMARDs to Conventional Anti-inflammatory Drugs (1 of 2)

There are few studies, of few patients, that specifically investigated the use of DMARDs in JIA. The DMARDs studied, the number of trials, the comparators and other interventions allowed, and the characteristics of the study population (number of patients with each category of disease at onset) are listed here.

In one study comparing D-penicillamine or hydroxychloroquine with placebo, NSAIDs, and acetaminophen, 142 patients had polyarticular disease, 11 had pauciarticular disease, and 9 had systemic disease at onset. In a second study comparing D-penicillamine or hydroxychloroquine with gold, NSAIDs, and acetaminophen, 49 patients had polyarticular disease and 23 had pauciarticular disease at onset.

In one trial comparing D-penicillamine with placebo and pyridoxine hydrochloride, 35 patients had polyarticular disease, 14 had pauciarticular disease, and 25 had systemic disease at onset.

In one study comparing sulfasalazine with NSAIDs, 32 patients had polyarticular disease and 37 had oligoarticular disease at onset.

In one study comparing azathioprine with placebo, NSAIDs, and prednisolone (when permitted), 16 patients had polyarticular disease, 9 had pauciarticular disease, and 7 had systemic disease at onset.